Skip to content ↓

MIT’s Koch Institute in strategic partnership with Ortho-McNeil-Janssen Pharmaceuticals

Organizations will collaborate in multiple areas of oncology research and technology development.
Press Inquiries

Press Contact:

Jessica Holmes
Phone: 617-253-2700
MIT News Office

Media Download

An artist's rendering of the new Koch Institute building.
Download Image
Caption: An artist's rendering of the new Koch Institute building.
Credits: Image: ELLENZWEIG

*Terms of Use:

Images for download on the MIT News office website are made available to non-commercial entities, press and the general public under a Creative Commons Attribution Non-Commercial No Derivatives license. You may not alter the images provided, other than to crop them to size. A credit line must be used when reproducing images; if one is not provided below, credit the images to "MIT."

Close
An artist's rendering of the new Koch Institute building.
Caption:
An artist's rendering of the new Koch Institute building.
Credits:
Image: ELLENZWEIG

The David H. Koch Institute of Integrative Cancer Research at MIT announced a major strategic partnership with Ortho-McNeil-Janssen Pharmaceuticals, Inc., and its affiliates, called TRANSCEND, whereby the parties will begin to collaborate in multiple areas of oncology research and technology development.

“Interdisciplinary collaboration is central to the mission and culture of the new Koch Institute as it is to MIT. By collaborating with a recognized medical innovation leader like Ortho-McNeil-Janssen Pharmaceuticals, Inc., the Koch Institute community will have enhanced opportunities to deliver the results of our research and technology to cancer patients and their families,” commented MIT President Susan Hockfield.

The partnership will begin with a five-year (with an option to renew) sponsored research effort involving the interdisciplinary faculty, students and staff from MIT’s Koch Institute. The teams will begin the collaboration by working in the areas of cancer diagnostics, cancer biology pre-malignancies, genetic models of disease, studying profiles of the tumor microenvironment while a Joint Scientific Steering Committee composed of MIT faculty members and Ortho-McNeil Janssen employees will jointly oversee TRANSCEND.

Tyler Jacks, Director of the Koch Institute, stated “The Koch Institute is developing novel approaches to address the unmet needs of cancer patients. By working closely with experts at Ortho-McNeil-Janssen Pharmaceuticals, we expect to advance our discoveries and new technologies rapidly to benefit individuals affected by this disease. Our faculty and trainees are energized by the new translational options made uniquely available through the TRANSCEND program."

The David H. Koch Institute for Integrative Cancer Research is a cancer research center affiliated with the Massachusetts Institute of Technology located in Cambridge, Mass. The Institute is one of seven National Cancer Institute-designated basic research centers in the U.S. The Koch Institute was launched in October 2007 and is physical home to approximately 25 MIT faculty members from both the Schools of Engineering and Science and convenes more than 1,000 researchers from across the MIT campus. The Koch Institute fosters and funds interdisciplinary collaborations in five key research areas: nanotherapeutics, detection and monitoring, metastasis, mapping drug sensitivity and resistance pathways, and cancer immunology.


Related Links

Related Topics

More MIT News

Wind turbines on the top of a hill

A healthy wind

Health benefits of using wind energy instead of fossil fuels could quadruple if the most polluting power plants are selected for dialing down, new study finds.

Read full story